Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease ...

Researchers assessed the safety, efficacy, and tolerability of various doses of zasocitinib among patients with moderate to severe plaque psoriasis.

For most people, a case of COVID-19 is easily treatable at this point in time. “Most” isn’t everyone, though, and the ...

The Pediatric Clinical Trials Office at Children’s of Alabama is helping lead the way in finding the best treatments for ...

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

ProJenX teamed with Unlearn to create digital twins of ALS patients as a placebo group in open-label extension of Phase 1 ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The trial (NCT06053840) enrolled 100 adult patients who received chloral hydrate treatment over 14 days and came from primary and secondary care sites. Patients were closely monitored by a virtual ...

Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clin ...

Pioneering Study in Parkinson's Disease to Advance Surgical Treatment Options RebrAIn, a leader in precise targeting solutions for deep brain stimulation (DBS) and lesion techniques, today announced ...